Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Generic Savings: REMS Obstruction, Not ANDA Backlog, Is Main Hindrance, AAM Says

Dollar sign made with drug pills

Related Content

REMS Could Block ANDAs With 'Legitimate Business Justification' In Senate Bill

Apr 30 2017

Brand Exclusivity 'Gaming' To Be Addressed At US FDA Meeting

May 26 2017

REMS Reform Seems Distant Goal For Generics After Limited Support At US House Hearing

Mar 03 2017

Generic Drug Roadblock: 74 Brands Subject To REMS, Other Restrictions

Jun 08 2017

FDA User Fee Bill: House Cmte. Makes Technical Changes, Adds Pricing Resolution

Jun 08 2017

Additional Topics

United States Pricing Debate Generic Drugs Drug Safety FDA Legislation BioPharmaceutical

More from Pricing Debate

More from Market Access

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window